Background Radiofrequency ablation (RFA) is a standard therapy for the treatment of hepatocellular carcinoma (HCC) with 3 or fewer tumors of up to 3 cm (early-stage HCC); when RFA is unsuccessful or unfeasible, transcatheter arterial chemoembolization (TACE) has often been performed. However, little information about the outcome of TACE for early-stage HCC has been reported and it is hard to decide whether to perform additional treatment following TACE in these difficult conditions. The aim of this study was to determine the risk factors for local or intrahepatic distant recurrence after TACE in early-stage HCC. Methods Among 1,560 newly diagnosed HCC patients who were admitted to Okayama University Hospital, 43 patients with early-stage HCC who received only TACE in at least one nodule were enrolled in this study. We analyzed the risk factors for local and distant recurrence by the Cox proportional hazard model. Results The local recurrence rates and intrahepatic distant recurrence rates at 3 months, 6 months, and 1 year were 18.6, 33.4, and 61.8%, and 2.8, 2.8, and 10.2%, respectively. Among 12 parameters examined as possible risk factors for recurrence, heterogeneous Lipiodol uptake (risk ratio 3.38; 95% confidence interval 1.14-10.60) and high serum des-gamma-carboxy prothrombin (DCP) (2.58; 1.03-7.14) were significantly correlated with local recurrence, and the presence of multiple tumors (10.64; 1.76-93.75) was significantly correlated with intrahepatic distant recurrence. Conclusions Heterogeneous Lipiodol uptake, high serum DCP, and multiple tumors are risk factors for recurrence in patients with early-stage HCC who have undergone palliative TACE.
Introduction
Hepatocellular carcinoma (HCC) has become increasingly detected at an early stage with the growing use of surveillance systems. The guidelines established by the American Association for the Study of Liver Disease (AASLD) [1] and the European Association for the Study of the Liver (EASL) [2] , and the Japanese ''EvidenceBased Guidelines'' recommend local treatment [3, 4] , such as radiofrequency ablation (RFA) or operation, for HCCs with 3 or fewer tumors of up to 3 cm in patients with good liver functional reserve and performance status. Additionally, RFA combined with transcatheter arterial chemoembolization (TACE) has been reported to be an efficient and safe treatment that provides overall survival rates similar to those achieved with surgical resection [5] [6] [7] . If the HCC is a hypervascular tumor, HCCs with 3 tumors or fewer of up to 3 cm are often subjected to sequential TACE followed by RFA, percutaneous ethanol injection therapy (PEIT), or operation regardless of the size because TACE is expected to enhance the efficacy of local therapy by reducing arterial blood flow [8] .
Occasionally, various factors such as poor liver functional reserve, difficult location for RFA treatment, and the presence of severe associated diseases in the elderly, or patients rejecting treatment, result in the selection of only TACE, even in candidates for local therapies. TACE is known to be effective for inoperable HCC [9, 10] ; however, little information has been reported about TACE for early-stage HCC, and it is hard to decide whether to perform additional treatment following TACE in these difficult conditions.
The objective of this retrospective cohort study was to determine whether only TACE for HCC with 3 tumors or fewer of up to 3 cm could control HCC; to achieve this objective we examined the recurrence rate and the risk factors for local and intrahepatic distant recurrences in such cases.
Subjects and methods

Patients
Patients were enrolled from among 1,560 newly diagnosed HCC patients who were admitted to Okayama University Hospital between 2002 and 2010. Inclusion criteria were as follows: (1) no previous treatment of HCC; (2) 3 or fewer nodules of up to 3 cm (early-stage HCC); (3) at least one nodule treated only by TACE as an initial treatment; (4) no planned local treatment such as RFA, PEIT, or operation performed within 30 days of TACE; (5) no vascular invasion; and (6) no extrahepatic metastasis. Exclusion criteria were: (1) complete cure of all nodules by RFA, PEIT, or operation and (2) follow-up period less than 1 year. Finally, 43 patients were selected and enrolled in this study. Of these patients, 6 died in the follow-up period. Five of these patients died due to liver disease and 1 died of heart failure. Informed consent for the use of their clinical data was obtained from all patients in this study. The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the ethics committee of the institute (approval # 458).
Diagnosis
HCC was diagnosed in accordance with AASLD guidelines. The diagnostic criteria for HCC via imaging were based on hyperattenuation in the the arterial phase and hypoattenuation in the portal phase on dynamic computed tomography (CT) or magnetic resonance imaging (MRI), and tumor stain on angiography. Ultrasonography (US) with perfluorobutane (Sonazoid; Daiichi Sankyo, Tokyo, Japan) and/or gadolinium ethoxybenzyl MRI (Gd-EOB-MRI) was performed in 30 (69.8%) patients. When we could not diagnose HCC by imaging only, fine-needle biopsy using abdominal US was performed as histological proof (3 cases). Recurrence of HCC was diagnosed in the same way as at the initial diagnosis. Treatment TACE was performed using the Seldinger technique followed by arterial embolization. After introducing a 4-Fr catheter through the femoral artery, hepatic arteriography and superior mesenteric arterial portovenography were performed to evaluate portal flow and the location of the tumors. When portal flow was sufficient, a 1.8-Fr or a 2.0-Fr microcatheter was placed in the feeding arteries at the closest point to the HCC. An emulsion consisting of 30-60 mg of epirubicin (Kyowa-Hakko, Tokyo, Japan) and 2-6 mL of iodized oil (Lipiodol Ultrafluid; Terumo, Tokyo, Japan) was injected into the artery supplying blood to the tumor, followed by embolization with 1-mm gelatin sponge particles (Gelfoam; Nihonkayaku, Tokyo, Japan). After embolization, CT angiography was performed to determine the extent of vascular occlusion and to assess blood flow in other arterial vessels. Patients were observed carefully, and analgesia (pentazocine; Astellas, Tokyo, Japan) was administered if necessary.
Lipiodol uptake was categorized as either homogeneous or heterogeneous by plain CT after TACE. Homogeneous uptake was defined as complete uptake of Lipiodol in the tumor without any defect, and the CT value in these cases was more than 200 Hounsfield Units. Uptake that did not meet the definition of homogeneous was considered as heterogeneous. Two experienced investigators (K. N. and H. O.) reviewed the CT images and evaluated the Lipiodol uptake. If the two investigators had different diagnoses, they discussed the difference and reached agreement.
Follow up
Patients were assessed every 1-3 months by serum biochemistry, dynamic CT, dynamic MRI, or US. Local recurrence was defined as the appearance of a viable tumor in contact with or inside the treated area. Intrahepatic distant recurrence was defined as the occurrence of a new HCC in the liver that did not meet the definition of local recurrence. When recurrence was detected, TACE, RFA, PEIT, or surgical resection was performed depending on the condition of the recurrence and the background liver function. Patients were followed until loss to follow up, death, or 31 January 2011.
Statistical analysis
The following 12 parameters were used for analyzing the risk factors for recurrence: age, sex, viral markers (hepatitis B virus surface antigen and hepatitis C virus antibody), alcohol intake, liver function, size of tumors, number of tumors, location of tumors (within 10 mm of the surface of the liver or not), serum tumor markers [alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP)], and the status of Lipiodol uptake.
Recurrence rates were estimated using the KaplanMeier method and differences between groups were compared using the log-rank test. The Cox proportional hazard model was used to analyze the predisposing factors for recurrence. All statistical analyses were performed using JMP version 9 (JMP Japan, Tokyo, Japan). All reported P values are 2-sided, with P \ 0.05 considered statistically significant.
Results
Patient background
A total of 43 patients met the criteria of this study. The total number of HCC nodules was 54. There were 27 males (63%) and 16 females (37%) aged 50-85 years (mean: 71 years), and 34 patients (79%) were infected with hepatitis C virus and 6 (14%) with hepatitis B virus. Twenty-three patients (53%) were habitual drinkers. Thirty-four patients (79%) had a single tumor in the initial treatment. Thirty-six patients (84%) had recurrence (Table 1) . Eleven (26%), 23 (53%), and 9 (21%) patients were treated with only TACE because of poor liver functional reserve, difficult location for RFA, and old age, respectively. Of the 11 patients who had poor liver function, 1 patient was Child C and 10 patients were Child B. Although the Japanese guidelines for treatment of HCC recommend RFA or operation for the treatment of small HCC in patients with Child A/B stage, these 10 Child B patients had poor conditions such as uncontrollable ascites or low albumin, so that it was quite difficult to perform RFA or operation. In the 23 patients who had a difficult location for RFA, the nodules were located beside the portal vein in 5 patients, beside the digestive tract in 4 patients, beside the gallbladder in 4 patients, beside the inferior vena cava in 3 patients, beside the collateral veins on the surface of liver in 3 patients, beside the bile duct in 3 patients, and beside the heart in 1 patient.
Recurrence rate
Local recurrence and intrahepatic distant recurrence were observed in 29 patients and 14 patients, respectively, and 7 of these patients showed both local and intrahepatic distant recurrences at the same time.
The total recurrence rates at 3 months, 6 months, and 1 year were 20.9, 35.3, and 68.5%, respectively. The local recurrence rates and intrahepatic distant recurrence rates at 3 months, 6 months, and 1 year were 18.6, 33.4, and 61.8%, and 2.8, 2.8, and 10.2%, respectively (Fig. 1) . Thirteen patients had local recurrences within 180 days. Eleven patients received RFA and and 11 patients received TACE for the therapy of local recurrence. Eight patients received RFA, 5 patients received TACE, and 1 patient received PEIT for the therapy of intrahepatic distant recurrence. No difference in the therapies was observed between the local recurrence group and the distant recurrence group.
Factors related to local recurrence
Of the 12 factors analyzed, heterogeneous Lipiodol uptake (risk ratio 3.19; 95% confidence interval 1.41-7.90; P = 0.004) and high serum DCP (2.37; 1.06-5.83; 0.034) were correlated with local recurrence by univariate analysis. The factor of location was not associated with local recurrence on univariate analysis. Factors exhibiting significance in the univariate analysis and reported to be correlated with recurrence; namely, DCP, age, number of HCCs, liver function, size of HCC, extent of Lipiodol uptake, HCV, and location of HCC, were further analyzed using the Cox multivariate proportional hazard model [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . On multivariate analysis, only heterogeneous Lipiodol uptake (risk ratio 3.38; 95% confidence interval 1.14-10.60; P = 0.027) and high serum DCP (2.58; 1.03-7.14; 0.042) were significantly correlated with local recurrence ( Table 2) .
Factors related to intrahepatic distant recurrence
In the same way as for factors related to local recurrence, the 12 factors were analyzed, and the factor of multiple tumors (3.98; 1.02-13.50; 0.047) was correlated with intrahepatic distant recurrence by univariate analysis. On multivariate analysis with the factors serum DCP, age, tumor number, Child-Pugh score, tumor size, Lipiodol uptake, HCV, and tumor location, the presence of multiple tumors (10.64; 1.76-93.75; 0.010) was significantly correlated with recurrence (Table 3) .
Discussion
While RFA is considered as the first choice for the treatment of early-stage HCC, TACE could be another option when RFA is unsuccessful or unfeasible. Livraghi [21] reported that RFA was not feasible in 6.0% of patients because of a high-risk tumor location or poor detection on ultrasonography (US). However, it is hard to decide whether to treat these patients with additional locoregional therapy because there have been few reported studies examining the outcomes of these patients in detail.
In the present study, we examined the clinical courses of 43 patients treated with palliative TACE for HCC with 3 tumors or fewer of up to 3 cm. More than 80% of the patients (36/43, 84%) had recurrence and most of them (29/ 36, 80%) exhibited local recurrence. The recurrence rate was higher than that for local ablation. The recurrence rates of the patients treated with RFA or operation at 3 months, Fig. 1 Local and distant recurrences after transcatheter arterial chemoembolization. The local recurrence rates (solid line) and intrahepatic distant recurrence rates (dotted line) at 3 months, 6 months, and 1 year were 18.6, 33.4, and 61.8%, and 2.8, 2.8, and 10.2%, respectively Table 1 footnote * Significant value 6 months, and 1 year at our institution during the same period were 2.8, 9.6, and 24.5%, respectively. Heterogeneous Lipiodol uptake and high serum DCP were significantly correlated with local recurrence, whereas the presence of multiple tumors was significantly correlated with intrahepatic distant recurrence.
The risk factors for recurrence after TACE in patients with HCC have been described in several reports. These include the extent of Lipiodol uptake, location of HCC, size of HCC, tumor markers, viral markers, number of HCCs, age, and liver function [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, most of these studies were on TACE for advanced HCC. In the present study, we examined the risk factors for earlystage HCC and revealed that only the extent of Lipiodol uptake and the serum DCP level were correlated with local recurrence, which is the most common type of recurrence after TACE. In early-stage HCCs, most of the tumors might be highly differentiated and less invasive, so that the tumors can be controlled merely by complete obstruction of their blood supply. Thus, only high DCP would be an additional risk factor, because HCC with high DCP showed a poorer differentiation grade than HCC with low DCP [22] . Our results suggest that it is better to treat early-stage HCC showing high serum DCP as well as incomplete Lipiodol uptake not only with TACE but also with additional locoregional treatment if possible.
Of note, we found that intrahepatic distant recurrence was observed in patients with multiple tumors, indicating that some of these tumors were intrahepatic metastases and that undetectable small HCCs might have already existed before the TACE was performed.
A meta-analysis showed that chemoembolization could improve the survival of well-selected patients with unresectable HCC [23] ; in addition, there is a report that chemoembolization had an effect on HCC even in patients with poor liver function [24] . However, the efficacy of TACE for treating HCC at an early stage has not been well elucidated. Although we could not show a survival benefit of TACE in early-stage HCC, to the best of our knowledge, this is the first report about the outcome of TACE for HCC with 3 tumors or fewer of up to 3 cm.
While new technologies such as artificial pleural effusion and ascites, or real-time virtual sonography (RVS), have increased the number of patients eligible for RFA, the age of HCC patients is gradually increasing, so that, when considering the treatment guideline algorithm for HCC, more patients would be excluded from such treatment owing to the presence of complications and poor performance status, among other factors. Eventually, we may not be able to avoid the selection of palliative TACE instead of RFA and operation. This study helped us to decide whether additional treatment should be considered in patients with difficult conditions according to the treatment algorithms .
In conclusion, palliative TACE could be effective for HCC with 3 tumors or fewer of up to 3 cm. Lipiodol uptake, serum DCP, and the number of tumors (C2) are the most important risk factors for recurrence in these HCCs treated with palliative TACE. Patients showing heterogeneous Lipiodol uptake after TACE should not be left untreated if at all possible.
Acknowledgments This study was supported by KAKENHI 23590976. 
